HCA stock forecast, quote, news & analysis

Key Takeaways

• HCA Healthcare shares have advanced roughly 8% over the trailing 30 days, a steady climb that leaves the stock well above its 52-week low of about $354 and below its 52-week high near $556.
• As of late October 2026, HCA traded around $472 per share, with a market capitalization of approximately $101 billion and a price-to-earnings ratio in the mid-teens.
• Second-quarter 2026 results came in ahead of consensus, with revenue of $20.23 billion and diluted earnings per share of $7.59, up 11% year over year.
• Management revised full-year 2026 guidance to revenue of $77.0–$79.5 billion and diluted EPS of $28.70–$30.50, reflecting payer-mix pressure from the expiration of enhanced premium tax credits.
• Several firms have turned more constructive on the shares, including RBC Capital (Outperform, $496 target), TD Cowen (Buy, $460), and BMO Capital (Outperform, $495).
• For more detail, explore HCA's Price Targets, Earnings, and Forecast pages.
• Discover top-performing automated strategies on Trending AI Robots.

Current Market Snapshot

HCA Healthcare's stock has moved steadily higher in recent weeks, gaining about 8% over the past 30 days on resilient hospital volumes and improving investor sentiment toward healthcare services. The shares remain in a broad recovery range, with a 52-week span of roughly $354 to $557. The company carries a trailing dividend yield near 0.7% and a beta of about 1.1, indicating slightly above-market volatility relative to the broader equity market. Analysts broadly rate the stock a Buy, with an average 12-month price target near $460, though several recently raised targets sit meaningfully higher.

HCA Healthcare (HCA) Business Overview and Competitive Position

HCA Healthcare is the largest for-profit hospital operator in the United States. Headquartered in Nashville, Tennessee, the company operates approximately 190 hospitals and roughly 2,600 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers, and physician clinics, across 19 states and the United Kingdom. Its scale gives HCA meaningful cost advantages over smaller and not-for-profit rivals, supporting industry-leading operating margins.

The company benefits from long-term demographic tailwinds, including an aging population that consumes more healthcare services, and maintains strong local positions in faster-growing markets such as Florida and Texas. HCA complements its acute-care footprint with a large outpatient network and a multi-billion-dollar capital expenditure program aimed at adding inpatient beds and ambulatory capacity. It also returns capital to shareholders through dividends and share repurchases.

Recent Developments Driving HCA

HCA's second-quarter 2026 report, released in late July, set the tone for the recent advance. Revenue rose 8.7% year over year to $20.23 billion, and diluted EPS climbed 11% to $7.59, both beating consensus estimates. Same-facility admissions and equivalent admissions increased 2.5% and 2.7%, respectively, while emergency room visits rose 3.6%, underscoring durable underlying demand.

The dominant headwind remains the expiration of enhanced premium tax credits, which reduced health-insurance-exchange enrollment and increased the number of uninsured patients. Management now expects an unfavorable exchange-related impact on adjusted EBITDA of roughly $1.0 billion to $1.2 billion for 2026, partially offset by incremental Medicaid supplemental payment benefits of $300 million to $500 million, including a Florida directed payment program.

Against that backdrop, analyst sentiment has improved. RBC Capital raised its price target to $496 from $435 with an Outperform rating, TD Cowen lifted its target to $460 from $431 with a Buy rating, and BMO Capital initiated coverage with an Outperform rating and a $495 target. HCA's third-quarter 2026 results are scheduled for late October, giving investors a fresh look at volume trends and cost discipline.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of the platform's automated trading strategies. While Tickeron offers hundreds of AI trading bots covering thousands of tickers, only the top-performing and most relevant bots appear in this featured section. These bots vary by strategy, timeframe, and performance metrics, allowing users to compare approaches across different market conditions. The page is designed to help traders and investors discover data-driven, rules-based systems rather than relying solely on discretionary decision-making. For those interested in exploring automated trading tools, Trending AI Robots offers a practical starting point.

2026 Outlook and What Investors Should Watch

Looking ahead, investors will focus on several factors. First, HCA's third-quarter results will provide clarity on whether resilient demand is offsetting the exchange-driven payer-mix shift. Management expects stronger adjusted EBITDA growth in the fourth quarter relative to the third, so commentary on that trajectory will be closely watched.

Policy developments also matter. Potential changes to Medicaid eligibility, work requirements, and supplemental payment programs could influence reimbursement, and HCA has indicated it is preparing through litigation and patient support. Elective surgery volumes, which have lagged emergency procedures, remain a key swing factor, as do labor costs, inflation, and interest rates. Finally, the company's cost-resiliency program, AI-enabled efficiency initiatives, and multi-billion-dollar capacity expansion will shape margins and long-term growth. These dynamics, rather than any single catalyst, are likely to drive HCA's performance through 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations